Financials in USD. Standardized financial statements.
A compact view of how ASLAN Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $12.00M | $0 | $0 | $0 | $3.00M | $0 | $0 | $11.49M | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $348,498 | $331,752 | $282,224 | $297,758 | $407,259 | $241,556 | $209,087 | $124,370 | $52,087 | $0 |
| Gross Profit? | $11.65M | -$331,752 | -$282,224 | -$297,758 | $2.59M | -$241,556 | -$209,087 | $11.36M | -$52,087 | $0 |
| Gross Margin? | +97.1% | 0.0% | 0.0% | 0.0% | +86.4% | 0.0% | 0.0% | +98.9% | 0.0% | 0.0% |
| Operating Expenses? | $55.39M | $47.88M | $33.85M | $16.48M | $48.17M | $42.35M | $39.94M | $20.02M | $12.84M | $7.31M |
| Operating Income? | -$43.74M | -$47.88M | -$33.85M | -$16.48M | -$45.58M | -$42.35M | -$39.94M | -$8.66M | -$12.84M | -$7.31M |
| EBITDA? | -$39.40M | -$47.28M | -$29.45M | -$15.43M | -$45.31M | -$41.44M | -$40.07M | -$8.41M | -$12.29M | -$7.04M |
| Income Before Tax | -$44.09M | -$51.28M | -$31.59M | -$16.97M | -$46.66M | -$42.17M | -$40.71M | -$9.00M | -$13.33M | -$7.36M |
| Income Tax Expense | $132,667 | $99,221 | $3.12M | $934,921 | $408,002 | $14,439 | -$342,458.831 | $0 | $500,028 | $0 |
| Net Income? | -$44.22M | -$51.38M | -$34.71M | -$17.91M | -$47.07M | -$42.19M | -$40.71M | -$9.00M | -$13.33M | -$7.36M |
| EPS? | $-10.76 | $-14.72 | $-10.64 | $-9.32 | $-29.00 | $-28.16 | $-32.72 | $-6.92 | $-24.20 | $-115.24 |
| Diluted EPS? | $-10.76 | $-14.72 | $-10.64 | $-9.32 | $-29.00 | $-28.16 | $-31.28 | $-6.92 | $-24.20 | $-115.24 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality